Cyclacel Pharmaceuticals Changes Address

Ticker: BGMSP · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1130166

Sentiment: neutral

Topics: corporate-action, address-change

Related Tickers: CYCC

TL;DR

Cyclacel Pharma moved its HQ to Malaysia. Big change!

AI Summary

On June 3, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's address is now Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing signals a significant operational change for Cyclacel Pharmaceuticals, indicating a potential relocation or restructuring of its corporate headquarters.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a change in address and does not contain information about financial performance or strategic shifts that would inherently increase risk.

Key Players & Entities

FAQ

What is the new address of Cyclacel Pharmaceuticals, Inc.?

The new address is Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200, Kuala Lumpur, Malaysia.

What is the filing date of this 8-K report?

The report was filed on June 3, 2025.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What was the former company name or a previous name for Cyclacel Pharmaceuticals, Inc.?

The former company name was XCYTE THERAPIES INC, with a date of name change on December 18, 2000.

What is the state of incorporation for Cyclacel Pharmaceuticals, Inc.?

The state of incorporation is Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing